Recombinant Human Coagulation FVIII
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recombinant Human Coagulation FVIII is one of 147 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.
5
Indications
8
Total Trials
1
Active Trials
146
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
698 competitors in Metastatic Colorectal Cancer
#DrugCompanyPhaseTrials
1Sutent
PfizerPhase 3
Trifluridine/tipiracil
AbbViePhase 3
Ofev
Boehringer IngelheimPhase 3
Legalon
BBukwang Pharmaceutical
Phase 3
Vatalanib
NovartisPhase 3
XL092
RochePhase 3
Recombinant Human Coagulation FVIII
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
FOLFOX-4
AmgenPhase 3
Brivanib Alaninate
GGynecologic Oncology Group
Phase 3
Mfolfoxiri
DDominik Paul Modest
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hemophilia A2 trials
Severe Hemophilia a1 trial
Esophageal Squamous Cell Carcinoma1 trial
Metastatic Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details